-
公开(公告)号:EP4392085A1
公开(公告)日:2024-07-03
申请号:EP22862438.3
申请日:2022-09-02
IPC分类号: A61L27/20 , A61L27/52 , A61L27/58 , C08J3/09 , A61K31/717 , A61K47/02 , A61K47/18 , A61K8/04 , A61K8/23 , A61K8/42 , A61K8/73 , A61K9/00 , A61K9/06 , A61P19/02 , A61Q19/08 , C08B15/00
CPC分类号: A61K8/42 , A61K9/06 , A61K31/717 , A61L27/20 , A61L27/52 , A61L27/58 , A61P19/02 , A61Q19/08 , C08L1/02 , A61K9/0019 , A61K47/38 , A61K36/899 , A61K8/731 , A61Q19/001 , A61K2800/9120130101 , A61K8/044
-
公开(公告)号:EP3384005B1
公开(公告)日:2022-02-02
申请号:EP16871684.3
申请日:2016-12-02
-
-
公开(公告)号:EP3694515A1
公开(公告)日:2020-08-19
申请号:EP18867181.2
申请日:2018-10-12
-
">
公开(公告)号:EP3601367A1
公开(公告)日:2020-02-05
申请号:EP18775234.0
申请日:2018-03-29
IPC分类号: C07K19/00 , C07K14/11 , C07K14/115 , C07K14/15 , C07K14/165 , C07K14/08 , A61P31/14
-
公开(公告)号:EP2077821B1
公开(公告)日:2019-08-14
申请号:EP07815360.8
申请日:2007-10-12
-
公开(公告)号:EP3515293A1
公开(公告)日:2019-07-31
申请号:EP17852006.0
申请日:2017-09-26
IPC分类号: A61B5/00 , A61B5/01 , A61B5/1455 , A61B5/024 , H04M1/725
-
公开(公告)号:EP2598517B1
公开(公告)日:2019-06-26
申请号:EP11811656.5
申请日:2011-07-28
-
公开(公告)号:EP3302710A1
公开(公告)日:2018-04-11
申请号:EP16802241.6
申请日:2016-06-01
发明人: WOODRUFF, Trent , ROLFE, Barbara
IPC分类号: A61P35/00 , A61P37/04 , A61K31/198 , A61K38/19
CPC分类号: A61K31/395 , A61K35/28 , A61K38/193 , A61K45/06 , A61K2035/124 , A61P35/00 , C07K14/723 , C12N5/0693 , A61K2300/00
摘要: The present invention discloses the use of a complement 3a receptor (C3aR) antagonist and a mobilizer of hematopoietic stem cells and/or progenitor cells in methods and compositions for stimulating or enhancing the development, mobilization, proliferation and/or differentiation of a neutrophil-containing leukocyte population that inhibits growth and/or spread of a tumor and for treating or preventing a hyperproliferative cell disorder.
-
公开(公告)号:EP2044197B8
公开(公告)日:2018-03-07
申请号:EP07784668.1
申请日:2007-07-23
IPC分类号: C12N5/0787 , A61K35/14 , A61P37/00
CPC分类号: C12N5/0642 , A61K2035/124 , C12N2500/02 , C12N2501/125 , C12N2501/145 , C12N2501/22
摘要: A method is provided for producing a population of post-mitotic cells of the neutrophil lineage, which method comprises the ex vivo steps of: (a) providing a population of cells comprising neutrophil progenitor cells; and (b) culturing the population of cells in an animal cell culture medium comprising (i) one or more early acting cytokines and (ii) one or more cytokines that differentiate said progenitor cells into a neutrophil specific lineage, under conditions of low oxidative stress, the culture medium being agitated when the cells are at a cell density at which oxygen transfer via the surface of the culture medium is insufficient for growth of the progenitor cells and the progeny thereof under static conditions, to produce a population of post-mitotic cells of the neutrophil lineage. The resulting population of cells can be used to increase the number of neutrophils in a patient.
-
-
-
-
-
-
-
-
-